Jian Huang

ORCID: 0000-0003-3340-5007
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Cancer Cells and Metastasis
  • Cancer Immunotherapy and Biomarkers
  • Immunotherapy and Immune Responses
  • Acute Myeloid Leukemia Research
  • MicroRNA in disease regulation
  • Immune cells in cancer
  • Cancer-related molecular mechanisms research
  • Immune Cell Function and Interaction
  • Cancer Genomics and Diagnostics
  • Breast Cancer Treatment Studies
  • Chemokine receptors and signaling
  • Cancer, Lipids, and Metabolism
  • RNA modifications and cancer
  • Circular RNAs in diseases
  • Hepatocellular Carcinoma Treatment and Prognosis
  • Cancer Research and Treatments
  • Cancer Mechanisms and Therapy
  • Cancer, Stress, Anesthesia, and Immune Response
  • Cancer, Hypoxia, and Metabolism
  • Chronic Myeloid Leukemia Treatments
  • Bladder and Urothelial Cancer Treatments
  • Chronic Lymphocytic Leukemia Research
  • Cancer-related Molecular Pathways
  • Cholangiocarcinoma and Gallbladder Cancer Studies
  • Advanced Breast Cancer Therapies

Zhejiang University
2016-2025

Second Affiliated Hospital of Zhejiang University
2016-2025

Zhejiang Cancer Hospital
2015-2025

First Affiliated Hospital Zhejiang University
2008-2025

Hangzhou Dianzi University
2025

Fuzhou General Hospital of Nanjing Military Command
2024

Second Affiliated Hospital of Nanjing Medical University
2024

Sun Yat-sen Memorial Hospital
2009-2024

Sun Yat-sen University
2009-2024

Central South University
2006-2024

Background— Current guidelines recommend coronary artery bypass graft surgery (CABG) when treating significant de novo left main (LM) stenosis; however, percutaneous intervention (PCI) has a class IIa indication for unprotected LM disease in selected patients. This analysis compares 5-year clinical outcomes PCI- and CABG-treated patients the Synergy Between PCI With Taxus Cardiac Surgery (SYNTAX) trial, largest trial this group to date. Methods Results— The SYNTAX randomly assigned 1800 with...

10.1161/circulationaha.113.006689 article EN Circulation 2014-04-04

One of the defining characteristics a pre-metastatic niche, fundamental requirement for primary tumor metastasis, is infiltration immunosuppressive macrophages. How these macrophages acquire their phenotype remains largely unexplored. Here, we demonstrate that tumor-derived exosomes (TDEs) polarize toward an characterized by increased PD-L1 expression through NF-kB-dependent, glycolytic-dominant metabolic reprogramming. TDE signaling TLR2 and NF-κB leads to glucose uptake. TDEs also...

10.1016/j.cmet.2021.09.002 article EN publisher-specific-oa Cell Metabolism 2021-09-23

γδT cells have been reported to exert immunosuppressive functions in multiple solid malignant diseases, but their functional subpopulation breast cancer (BC) is still undetermined. Here, we collected 40 paired BC and normal tissue samples from Chinese patients for analysis. First, showed that γδT1 comprise the majority of CD3+ T BC; next, found CD73+γδT1 were predominant regulatory T-cell (Treg) population BC, prevalence peripheral blood was also related tumour burden. In addition, an effect...

10.1038/s41392-020-0129-7 article EN cc-by Signal Transduction and Targeted Therapy 2020-04-28

Abstract Background The standard first‐line treatment for human epidermal growth factor receptor 2 (HER2)‐positive recurrent/metastatic breast cancer currently includes pertuzumab plus trastuzumab and docetaxel. This study aimed to evaluate the effectiveness of KN026, an anti‐HER2 bispecific antibody, docetaxel in HER2‐positive cancer. Methods open‐label, single‐arm, phase II enrolled patients with 19 centers across China from December 30, 2019 May 27, 2021. Patients were administered KN026...

10.1002/cac2.12662 article EN cc-by-nc-nd Cancer Communications 2025-01-18

Tumors that cannot make arginine undergo mitochondrial dysfunction in the absence of extracellular and die by autophagy.

10.1126/scisignal.2004761 article EN Science Signaling 2014-04-01

Colorectal cancer (CRC) is one of the most prevalent cancers globally and leading causes cancer-related deaths due to therapy resistance metastasis. Understanding mechanism underlying colorectal carcinogenesis essential for diagnosis treatment CRC. microRNAs (miRNAs) can act as either oncogenes or tumor suppressors in many cancers. A suppressor role miR-27b has recently been reported neuroblastoma, while no information about CRC available. In this study, we demonstrated that expression...

10.1371/journal.pone.0060687 article EN cc-by PLoS ONE 2013-04-12

The aim of the present study was to investigate association between microRNA (miR)-155 and apoptosis monocytes infected by Mycobacterium tuberculosis, examine effect forkhead box O3 (FOXO3) on miR‑155. analysed CD14+ in peripheral blood patients with active disposed THP‑1 human monocytic cell line BCG examined expression Furthermore, FOXO3 cells determined, wild- mutant-type luciferase reporter plasmids containing 3'‑untranslated regions (UTRs) were constructed analyse luciferase. Finally,...

10.3892/mmr.2015.4250 article EN Molecular Medicine Reports 2015-08-25

Tumor microenvironment (TME) promotes immune suppression through recruiting and expanding suppressive cells such as regulatory T (Tregs) to facilitate cancer progression. In this study, we identify a novel CD39+ γδTreg in human colorectal (CRC). γδTregs are the predominant have more potent immunosuppressive activity than CD4+ or CD8+ Tregs via adenosine-mediated pathway but independent of TGF-β IL-10. They also secrete cytokines including IL-17A GM-CSF, which may chemoattract myeloid-derived...

10.1080/2162402x.2016.1277305 article EN OncoImmunology 2017-01-06
Coming Soon ...